Nikkiel Lefebre
Family · Gresham, ORNPI 1801337746
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 38.3% of the total. Among family clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Collegium Pharmaceutical, Inc.$254
- Abbott$183
- Galderma Laboratories, L.p.$145
- GRT US Holding, Inc.$131
- Biohaven Pharmaceutical Holding Company Ltd.$119
- plus $895 from 19 others
What the payments were for
- Food & beverage$2,800100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $1,073 |
| Collegium Pharmaceutical, Inc. | 14 | $254 |
| Abbott | 9 | $183 |
| Galderma Laboratories, L.p. | 4 | $145 |
| GRT US Holding, Inc. | 3 | $131 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $119 |
| Pfizer | 7 | $118 |
| Bioventus LLC | 4 | $104 |
| Ipsen Biopharmaceuticals, Inc | 4 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Nevro Corp. | 4 | $64 |
| Amgen | 3 | $61 |
| Novartis | 3 | $44 |
| Relievant Medsystems, Inc. | 1 | $42 |
| Eisai Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $40 |
| Boston Scientific | 2 | $39 |
| Saluda Medical Americas, Inc. | 2 | $34 |
| Biodelivery Sciences International, Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Stimwave Technologies Incorporated | 2 | $23 |
| Averitas Pharma Inc. | 1 | $21 |
| Si-bone, Inc. | 1 | $14 |
| Avanos Medical | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,800 in reported general payments places this provider in the 95th percentile of 1,130 family providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 24 | $10,608 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 289 | $8,117 |
| Xtampza ErOxycodone Myristate | 14 | $7,405 |
| Fentanyl | 42 | $5,003 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 164 | $4,740 |
| Oxycodone Hcl | 211 | $3,423 |
| Morphine Sulfate ErMorphine Sulfate | 107 | $2,893 |
| Cyclobenzaprine Hcl | 50 | $902 |
| Buprenorphine Hcl | 17 | $785 |
| Tizanidine Hcl | 57 | $760 |
| Gabapentin | 38 | $690 |
| Methadone Hcl | 35 | $450 |
| Pregabalin | 25 | $354 |
| Hydromorphone Hcl | 12 | $116 |
| Tramadol Hcl | 20 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $254 | $7,40514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,130 family providers in Oregon.
Other family in Gresham
- Rachel PangilinanPortland$103K
- Jodeanna SweeneyCentral Point$45K
- Lani DoserPortland$45K
- David ArnopoleMedford$38K
- Heather HermanCorvallis$34K
- Amy BartramOregon City$33K
- Leah GaedekePortland$26K
- Bobbi Lee RothTualatin$23K
- Susan ToftePortland$21K
- Leah WessenbergPortland$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.